Seer (SEER) Liabilities and Shareholders Equity (2020 - 2026)
Seer (SEER) posted quarterly Liabilities and Shareholders Equity of $272.1 million for Q1 2026, down 21.63% year-over-year from $347.3 million in Q1 2025, and down 8.09% quarter-over-quarter from $296.1 million in Q4 2025.
Seer (SEER) Liabilities and Shareholders Equity (2020 - 2026) Analysis & Trends
Seer's Liabilities and Shareholders Equity history runs 7 years deep, the most recent figure standing at $272.1 million for Q1 2026.
- In Q1 2026, Liabilities and Shareholders Equity fell 21.63% year-over-year to $272.1 million; the TTM figure through Mar 2026 stood at $1.2 billion (down 20.25% YoY), while the FY2025 annual figure was $296.1 million, down 19.23% from the prior year.
- Liabilities and Shareholders Equity for Q1 2026 stood at $272.1 million, down from $296.1 million in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $527.1 million in Q1 2022, with the low at $272.1 million in Q1 2026.
- The 5-year median for Liabilities and Shareholders Equity is $422.0 million (2024), against an average of $410.1 million.
- The sharpest annual moves came in 2022 and 2026: Liabilities and Shareholders Equity fell 3.4% in 2022, then decreased 21.63% in 2026.
- Seer's Liabilities and Shareholders Equity stood at $487.9 million in 2022, then decreased by 10.59% to $436.3 million in 2023, then retreated by 15.97% to $366.6 million in 2024, then retreated by 19.23% to $296.1 million in 2025, then dropped by 8.09% to $272.1 million in 2026.
- Business Quant data shows SEER's Liabilities and Shareholders Equity at $272.1 million in Q1 2026, $296.1 million in Q4 2025, and $308.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Seer | 230.63 Mn | 230.63 Mn | 1.51 Mn | 256.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 256.64 Mn |
| Mar 31, 2026 | 272.13 Mn |
| Dec 31, 2025 | 296.08 Mn |
| Sep 30, 2025 | 308.61 Mn |
| Jun 30, 2025 | 322.49 Mn |
| Mar 31, 2025 | 347.26 Mn |
| Dec 31, 2024 | 366.60 Mn |
| Sep 30, 2024 | 383.42 Mn |
| Jun 30, 2024 | 406.61 Mn |
| Mar 31, 2024 | 421.96 Mn |
| Dec 31, 2023 | 436.27 Mn |
| Sep 30, 2023 | 444.85 Mn |
| Jun 30, 2023 | 461.20 Mn |
| Mar 31, 2023 | 472.79 Mn |
| Dec 31, 2022 | 487.93 Mn |
| Sep 30, 2022 | 500.21 Mn |
| Jun 30, 2022 | 516.30 Mn |
| Mar 31, 2022 | 527.09 Mn |
| Dec 31, 2021 | 539.14 Mn |
| Sep 30, 2021 | 527.84 Mn |